BriaCell Therapeutics Corp.
BCT.TO
TSX
| 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -29.64M | -28.71M | -26.31M | -19.43M | -11.59M |
| Total Depreciation and Amortization | 106.80K | 106.80K | 106.80K | 152.50K | 129.60K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -71.50K | -747.60K | -58.10K | -3.77M | -14.33M |
| Change in Net Operating Assets | -1.36M | 427.90K | -1.91M | -1.02M | 3.79M |
| Cash from Operations | -30.97M | -28.92M | -28.17M | -24.07M | -21.99M |
| Capital Expenditure | -- | -- | -- | -456.80K | -456.80K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -288.50K | -7.65M | -7.65M | -255.00K | -375.00K |
| Cash from Investing | -288.50K | -7.65M | -7.65M | -711.80K | -831.80K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 56.15M | 33.49M | 45.45M | 36.31M | 21.60M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 56.15M | 33.49M | 45.45M | 36.31M | 21.60M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 24.89M | -3.08M | 9.63M | 11.52M | -1.23M |